The use of p16/Ki-67 dual staining technology on cervical cytology of patients undergoing a LLETZ procedure. (September 2018)

• Record Type: Journal Article
• Authors: Packet, Bram; Poppe, Willy; Weynand, Birgit; Vanherck, Miet
• Is Part Of: European journal of obstetrics, gynecology, and reproductive biology. Volume 228(2018)
• Page Start: 191
• Page End: 196
• Publication Date: 2018-09
• Subjects: CINtec PLUS® cytology test -- Diagnostic cytology -- Conisation -- Triage -- p16/Ki-67 dual stain cytology; Obstetrics -- Periodicals; Gynecology -- Periodicals; Reproductive health -- Periodicals; Gynecology -- Periodicals; Obstetrics -- Periodicals; Reproduction -- Periodicals; Obstétrique -- Périodiques; Gynécologie -- Périodiques; Reproduction -- Périodiques; Verloskunde; Gynaecologie; Voortplanting (biologie); Gynecology; Obstetrics; Reproduction; Electronic journals; Periodicals; Electronic journals; 618.05
• DOI: 10.1016/j.ejogrb.2018.06.025
• Languages: English
• ISSNs: 0301-2115

Abstract

Abstract: Objectives: The main objective of this prospective observational study was to investigate the diagnostic performance of the p16/Ki-67 dual stain technique (DST) for detecting CIN 2+ in a LLETZ referral setting. Test performances were compared with HR-HPV testing and Pap cytology. Methods: All patients referred for a LLETZ procedure were candidates for participation in this trial. A total of 110 patients were enrolled between October 2016 and March 2017. From each participant, a cervical cytology sample was obtained before the onset of the LLETZ procedure. On each sample, the dual stain technique (Roche CINtec PLUS ® test), Pap cytology and an HPV DNA assay (identifying 17 different HPV types) were performed. Results: The overall disease prevalence of CIN 2+ was 56%. The mean age was 41 years, with 38% of patients being younger than 35 years. The overall sensitivity and specificity of the dual stain technique for detecting CIN 2+ was 94% (95% CI: 84.30–98.21%) and 58% (95% CI: 43.21–72.93%) respectively with a PPV of 74% (95% CI: 67.34–80.31%) and a NPV of 88% (95% CI: 72.48–94.90%). HR-HPV testing results in a similar sensitivity of 92% (95% CI: 82.17–97.33%) but considerable lower specificity of 21% (95% CI: 11.17–33.35%) compared to the dual stain technique. At an ASCUS or worse threshold, Pap cytology had the lowest sensitivity of 89% (95% CI 78.11–95.34%) compared to dual staining and HR-HPV testing. Specificity was better (48% with 95% CI of 33.29–62.81%) than that of HR-HPV testing but not as good as the DST. Conclusion: p16/Ki-67 dual staining provides high sensitivity and improved specificity compared to HR-HPV testing and Pap cytology for detecting CIN 2+, making it an interesting tool for identifying relevant disease in patients referred for a LLETZ procedure.